Elicio Therapeutics' Darrell Irvine co-authors research published in Science
Research conducted at the Irvine Lab at MIT's Koch Institute showed that activation of CAR-T cells in lymph nodes leads to massive CAR-T cell expansion and significant functional improvements. The AMP-CAR-T Platform combines CAR-T therapy with Amphiphile immunotherapies to amplify immune responses and combat solid tumors.